<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR4">
 <label>4.</label>
 <mixed-citation publication-type="other">Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph. Lancet HIV [Internet]. 2018 Jul [cited 2019 Mar 8];5(7):e347–56. Available from: 
  <ext-link ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S2352301818300912" xmlns:xlink="http://www.w3.org/1999/xlink">https://linkinghub.elsevier.com/retrieve/pii/S2352301818300912</ext-link>.
 </mixed-citation>
</ref>
